BioNxt Announces Enhanced Sublingual Product Development Pipeline with Innovative Solutions for Autoimmune Diseases and Longevity
BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT) is pleased to announce the expansion of its next-generation product pipeline. This includes proprietary Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablet) drug delivery systems targeting autoimmune diseases such as Multiple sclerosis ("MS"), Myasthenia gravis ("MG"), Lupus nephritis ("LN"), and Rheumatoid arthritis ("RA"), as well as an exciting initiative in the fast-growing longevity market. These advancements highlight BioNxt's commitment to developing innovative, patient-centric solutions to improve compliance, enhance drug bioavailability, and address critical unmet medical needs.